UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | I | J | K | L | M | N | O | P | R | S | T | V | W | Y
Number of items: 87.


Abdallah, QMA; Phillips, RM; Johansson, F; Helleday, T; Cosentino, L; Abdel-Rahman, H; Etzad, J; (2012) Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. BIOCHEMICAL PHARMACOLOGY , 83 (11) pp. 1514-1522. 10.1016/j.bcp.2012.02.017.

Adair, JR; Howard, PW; Hartley, JA; Williams, DG; Chester, KA; (2012) Antibody-drug conjugates - a perfect synergy. EXPERT OPINION ON BIOLOGICAL THERAPY , 12 (9) pp. 1191-1206. 10.1517/14712598.2012.693473.

Aksoy, E; Taboubi, S; Torres, D; Delbauve, S; Hachani, A; Whitehead, MA; Pearce, WP; (2012) The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol , 13 (11) pp. 1045-1054. 10.1038/ni.2426.

Alcolea, MP; Casado, P; Rodríguez-Prados, JC; Vanhaesebroeck, B; Cutillas, PR; (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics , 11 (8) pp. 453-466. 10.1074/mcp.M112.017483.

Arkenau, H-T; Saggese, M; Lemech, C; (2012) Advanced gastric cancer: Is there enough evidence to call second-line therapy standard? WORLD JOURNAL OF GASTROENTEROLOGY , 18 (44) pp. 6376-6378. 10.3748/wjg.v18.i44.6376. Gold open access

Arkenau, HT; Plummer, R; Molife, LR; Olmos, D; Yap, TA; Squires, M; Lewis, S; (2012) A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol , 23 (5) pp. 1307-1313. 10.1093/annonc/mdr451.

Asghar, U; Meyer, T; (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? JOURNAL OF HEPATOLOGY , 56 (3) pp. 686-695.


Bachner, M; Loriot, Y; Gross-Goupil, M; Zucali, PA; Horwich, A; Germa-Lluch, J-R; Kollmannsberger, C; (2012) 2-(18)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. ANNALS OF ONCOLOGY , 23 (1) pp. 59-64. 10.1093/annonc/mdr052.

Bagnobianchi, A; Spanswick, VJ; Bingham, JP; Kiakos, K; Suarez-Henriques, P; Smith, D; Yong, K; (2012) Persistence of drug-induced DNA interstrand cross-links distinguishes bendamustine from conventional DNA cross-linking agents. CANCER RESEARCH , 72 10.1158/1538-7445.AM2012-1766.

Banerji, U; van Doorn, L; Papadatos-Pastos, D; Kristeleit, R; Debnam, P; Tall, M; Stewart, A; (2012) A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clinical Cancer Research , 18 (9) 2687 - 2694.

Baud, MG; Leiser, T; Haus, P; Samlal, S; Wong, AC; Wood, RJ; Petrucci, V; (2012) Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J Med Chem , 55 (4) pp. 1731-1750. 10.1021/jm2016182.

Berenjeno, IM; Guillermet-Guibert, J; Pearce, W; Gray, A; Fleming, S; Vanhaesebroeck, B; (2012) Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J , 442 (1) pp. 151-159. 10.1042/BJ20111741.


Cain, RJ; Vanhaesebroeck, B; Ridley, AJ; (2012) Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration. Int J Biochem Cell Biol , 44 (11) pp. 1929-1936. 10.1016/j.biocel.2012.07.009.

Campbell, NH; Abd Karim, NH; Parkinson, GN; Gunaratnam, M; Petrucci, V; Todd, AK; Vilar, R; (2012) Molecular Basis of Structure-Activity Relationships between Salphen Metal Complexes and Human Telomeric DNA Quadruplexes. JOURNAL OF MEDICINAL CHEMISTRY , 55 (1) pp. 209-222. 10.1021/jm201140v.

Chapman, MH; Tidswell, R; Dooley, JS; Sandanayake, NS; Cerec, V; Deheragoda, M; Lee, AJX; (2012) Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. JOURNAL OF HEPATOLOGY , 56 (4) pp. 877-885.


Dunlop, MG; Dobbins, SE; Farrington, SM; Jones, AM; Palles, C; Whiffin, N; Tenesa, A; (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet , 44 (7) pp. 770-776. 10.1038/ng.2293.


Falchook, GS; Long, GV; Kurzrock, R; Kim, KB; Arkenau, TH; Brown, MP; Hamid, O; (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet , 379 (9829) pp. 1893-1901. 10.1016/S0140-6736(12)60398-5.

Fenton, TR; Nathanson, D; Ponte de Albuquerque, C; Kuga, D; Iwanami, A; Dang, J; Yang, H; (2012) Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. PNAS USA , 109 (35) 14164 - 14169. 10.1073/pnas.1211962109. Green open access

Fernandez, AF; Assenov, Y; Ignacio Martin-Subero, J; Balint, B; Siebert, R; Taniguchi, H; Yamamoto, H; (2012) A DNA methylation fingerprint of 1628 human samples. GENOME RESEARCH , 22 (2) pp. 407-419. 10.1101/gr.119867.110.

Fizazi, K; Scher, HI; Molina, A; Logothetis, CJ; Chi, KN; Jones, RJ; Staffurth, JN; (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. LANCET ONCOLOGY , 13 (10) pp. 983-992. 10.1016/S1470-2045(12)70379-0.


Garelnabi, EAE; Pletsas, D; Li, L; Kiakos, K; Karodia, N; Hartley, JA; Phillips, RM; (2012) Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR. ACS MEDICINAL CHEMISTRY LETTERS , 3 (12) pp. 965-968. 10.1021/ml300132t.

Gerlinger, M; Rowan, AJ; Horswell, S; Larkin, J; Endesfelder, D; Gronroos, E; Martinez, P; (2012) Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. NEW ENGLAND JOURNAL OF MEDICINE , 366 (10) pp. 883-892.

Gerlinger, M; Santos, CR; Spencer-Dene, B; Martinez, P; Endesfelder, D; Burrell, RA; Vetter, M; (2012) Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. JOURNAL OF PATHOLOGY , 227 (2) pp. 146-156. 10.1002/path.4006.

Gibson, F; Fern, L; Whelan, J; Pearce, S; Lewis, IJ; Hobin, D; Taylor, RM; (2012) A scoping exercise of favourable characteristics of professionals working in teenage and young adult cancer care: 'thinking outside of the box'. EUROPEAN JOURNAL OF CANCER CARE , 21 (3) pp. 330-339. 10.1111/j.1365-2354.2011.01322.x.

Gibson, F; Shipway, L; Barry, A; Taylor, RM; (2012) What's It Like When You Find Eating Difficult Children's and Parents' Experiences of Food Intake. CANCER NURSING , 35 (4) pp. 265-277. 10.1097/NCC.0b013e31822cbd40.

Goncalves, M; Walker-Samuel, S; Johnson, SP; Pedley, RB; Lythgoe, MF; (2012) Investigating Tumour Vascular Connectivity With MRI and Independent Component Analysis. In: (Proceedings) 22nd Biennial Congress of the European-Association-for-Cancer-Research. (pp. S205-S205). ELSEVIER SCI LTD

Greco, FA; Oien, K; Erlander, M; Osborne, R; Varadhachary, G; Bridgewater, J; Cohen, D; (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. ANNALS OF ONCOLOGY , 23 (2) pp. 298-304. 10.1093/annonc/mdr306.


Hall, PS; McCabe, C; Stein, RC; Cameron, D; (2012) Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. Journal of the National Cancer Institute , 104 (1) pp. 56-66. 10.1093/jnci/djr484.

Hartley, JA; Hamaguchi, A; Suggitt, M; Gregson, SJ; Thurston, DE; Howard, PW; (2012) DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. INVESTIGATIONAL NEW DRUGS , 30 (3) pp. 950-958. 10.1007/s10637-011-9647-z.

Hartley, JA; Hochhauser, D; (2012) Small molecule drugs - optimizing DNA damaging agent-based therapeutics. CURRENT OPINION IN PHARMACOLOGY , 12 (4) pp. 398-402. 10.1016/j.coph.2012.03.008.

Ho, KK; McGuire, VA; Koo, CY; Muir, KW; de Olano, N; Maifoshie, E; Kelly, DJ; (2012) Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem , 287 (2) pp. 1545-1555. 10.1074/jbc.M111.284224.

Howie, AJ; (2012) Diagnosis of amyloid using Congo red. In: Picken, MM and Dogan, A and Herrera, G, (eds.) Amyloid and related disorders: surgical pathology and clinical correlations. (167 - 174). Springer: New York, USA.


Iorns, E; Ward, TM; Dean, S; Jegg, A; Thomas, D; Murugaesu, N; Sims, D; (2012) Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. BREAST CANCER RESEARCH AND TREATMENT , 135 (1) pp. 79-91. 10.1007/s10549-012-2068-7.

Ip, L; Cia-Viciano, F; Spanswick, V; Pouigiannis, G; Cantley, L; Hartley, J; Hochhauser, D; (2012) Loss of the tumour suppressor inositol polyphosphate 4-phosphatase type II in ovarian cancer-implications for therapy. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE , 30 S19-S19.

Irshad, S; Grigoriadis, A; Lawler, K; Ng, T; Tutt, A; (2012) Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care (Basel) , 7 (4) pp. 273-280. 10.1159/000341529.


Johnson, RJ; Davies, A; Lee, S-M; Gilson, D; Smith, P; Qian, W; Braganca, N; (2012) A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010). In: (Proceedings) 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). AMER SOC HEMATOLOGY

Johnson, SP; Laufer, JG; Zhang, EZ; Beard, PC; Pedley, RB; (2012) Determination of Differential Tumour Vascular Pathophysiology in Vivo by Photoacoustic Imaging. In: (Proceedings) 22nd Biennial Congress of the European-Association-for-Cancer-Research. (pp. S186-S187). ELSEVIER SCI LTD


Karpathakis, A; Caplin, M; Thirlwell, C; (2012) Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours? ENDOCRINE-RELATED CANCER , 19 (3) R73-R92. 10.1530/ERC-12-0050.

Klionsky, DJ; Abdalla, FC; Abeliovich, H; Abraham, RT; Acevedo-Arozena, A; Adeli, K; Agholme, L; (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. AUTOPHAGY , 8 (4) pp. 445-544. 10.4161/auto.19496.


Laufer, J; Jathoul, A; Johnson, P; Zhang, E; Lythgoe, M; Pedley, RB; Pule, M; (2012) In vivo photoacoustic imaging of tyrosinase expressing tumours in mice. PHOTONS PLUS ULTRASOUND: IMAGING AND SENSING 2012 , 8223 (ARTN 822) 10.1117/12.907006.

Laufer, J; Johnson, P; Zhang, E; Treeby, B; Cox, B; Pedley, B; Beard, P; (2012) In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy. JOURNAL OF BIOMEDICAL OPTICS , 17 (5) 10.1117/1.JBO.17.5.056016.

Lee, AJX; Roylance, R; Sander, J; Gorman, P; Endesfelder, D; Kschischo, M; Jones, NP; (2012) CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. JOURNAL OF PATHOLOGY , 226 (3) pp. 482-494. 10.1002/path.2998.

Lee, AJX; Swanton, C; (2012) Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics. BIOCHEMICAL PHARMACOLOGY , 83 (8) pp. 1013-1020. 10.1016/j.bcp.2011.12.008.

Lemech, C; Arkenau, HT; (2012) Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol , 6 pp. 53-66. 10.4137/CMO.S5855. Gold open access

Lemech, C; Infante, J; Arkenau, H-T; (2012) The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY , 4 (2) pp. 61-73. 10.1177/1758834011432949. Gold open access

Lombardo, CM; Welsh, SJ; Strauss, SJ; Dale, AG; Todd, AK; Nanjunda, R; Wilson, WD; (2012) A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 22 (18) pp. 5984-5988. 10.1016/j.bmcl.2012.07.009.

Lucas, G; Win, N; Calvert, A; Green, A; Griffin, E; Bendukidze, N; Hopkins, M; (2012) Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. VOX SANGUINIS , 103 (1) pp. 10-17. 10.1111/j.1423-0410.2011.01570.x.


Maharaj, L; Popat, R; Gribben, JG; Joel, S; (2012) IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model. In: (Proceedings) 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). AMER SOC HEMATOLOGY

Maxwell, MJ; Tsantikos, E; Kong, AM; Vanhaesebroeck, B; Tarlinton, DM; Hibbs, ML; (2012) Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease. J Autoimmun , 38 (4) pp. 381-391. 10.1016/j.jaut.2012.04.001.

McGranahan, N; Burrell, RA; Endesfelder, D; Novelli, MR; Swanton, C; (2012) Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO REPORTS , 13 (6) pp. 528-538. 10.1038/embor.2012.61.

McTiernan, A; Jinks, RC; Sydes, MR; Uscinska, B; Hook, JM; van Glabbeke, M; Bramwell, V; (2012) Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. European Journal of Cancer , 48 (5) 703 - 712. 10.1016/j.ejca.2011.09.012. Green open access

Meyer, R; Kulinskaya, E; Briassoulis, G; Taylor, RM; Cooper, M; Pathan, N; Habibi, P; (2012) The Challenge of Developing a New Predictive Formula to Estimate Energy Requirements in Ventilated Critically Ill Children. NUTRITION IN CLINICAL PRACTICE , 27 (5) pp. 669-676. 10.1177/0884533612448479.


Nagano, K; Akpan, A; Warnasuriya, G; Corless, S; Totty, N; Yang, A; Stein, R; (2012) Functional Proteomic Analysis of Long-term Growth Factor Stimulation and Receptor Tyrosine Kinase Coactivation in Swiss 3T3 Fibroblasts. MOLECULAR & CELLULAR PROTEOMICS , 11 (12) pp. 1690-1708. 10.1074/mcp.M112.019778.

Natrajan, R; Mackay, A; Lambros, MB; Weigelt, B; Wilkerson, PM; Manie, E; Grigoriadis, A; (2012) A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. JOURNAL OF PATHOLOGY , 227 (1) pp. 29-41. 10.1002/path.4003.


Ortega-Molina, A; Efeyan, A; Lopez-Guadamillas, E; Muñoz-Martin, M; Gómez-López, G; Cañamero, M; Mulero, F; (2012) Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab , 15 (3) pp. 382-394. 10.1016/j.cmet.2012.02.001.


Pan, X; Hartley, JM; Hartley, JA; White, KN; Wang, Z; Bligh, SWA; (2012) Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. PHYTOMEDICINE , 19 (7) pp. 618-624. 10.1016/j.phymed.2012.02.003.

Perez-Medina, C; Patel, N; Robson, M; Badar, A; Lythgoe, MF; Arstad, E; (2012) Evaluation of a I-125-labelled benzazepinone derived voltage-gated sodium channel blocker for imaging with SPECT. ORGANIC & BIOMOLECULAR CHEMISTRY , 10 (47) pp. 9474-9480. 10.1039/c2ob26695d.

Pericleous, M; Lumgair, H; Baneke, A; Morgan-Rowe, L; E Caplin, M; Luong, TV; Thirlwell, C; (2012) Appendiceal goblet cell carcinoid tumour: a case of unexpected lung metastasis. Case Rep Oncol , 5 (2) pp. 332-338.

Ploquin, A; Olmos, D; Lacombe, D; A'Hern, R; Duhamel, A; Twelves, C; Marsoni, S; (2012) Prediction of early death among patients enrolled in phase i trials: Development and validation of a new model based on platelet count and albumin. British Journal of Cancer , 107 (7) pp. 1025-1030. 10.1038/bjc.2012.371.


Raja, F; Kaler, M; Amadeo, G; Hadwin, R; Kristeleit, RS; McCormack, M; Mould, T; (2012) LATE RELAPSED OVARIAN CANCER. International Journal of Gynecological Cancer , 22 (Suppl 3)

Raja, FA; Hook, JM; Ledermann, JA; (2012) Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. CANCER TREATMENT REVIEWS , 38 (6) pp. 662-672. 10.1016/j.ctrv.2011.11.009.

Rajkumar, VS; Boxer, G; Robson, M; Muddle, J; Papastavrou, Y; Pedley, RB; (2012) A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. TUMOR BIOLOGY , 33 (6) pp. 2019-2029. 10.1007/s13277-012-0461-9.

Ramage, JK; Ahmed, A; Ardill, J; Bax, N; Breen, DJ; Caplin, ME; Corrie, P; (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). GUT , 61 (1) pp. 6-32. 10.1136/gutjnl-2011-300831.

Rossi, A; Di Maio, M; Chiodini, P; Rudd, RM; Okamoto, H; Skarlos, DV; Frueh, M; (2012) Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. JOURNAL OF CLINICAL ONCOLOGY , 30 (14) pp. 1692-1698. 10.1200/JCO.2011.40.4905.


Satam, V; Babu, B; Chavda, S; Savagian, M; Sjoholm, R; Tzou, S; Liu, Y; (2012) Novel diamino imidazole and pyrrole-containing polyamides: Synthesis and DNA binding studies of mono- and diamino-phenyl-ImPy*Im polyamides designed to target 5 '-ACGCGT-3 '. BIOORGANIC & MEDICINAL CHEMISTRY , 20 (2) pp. 693-701. 10.1016/j.bmc.2011.12.010.

Satam, V; Babu, B; Porte, A; Savagian, M; Lee, M; Smeltzer, T; Liu, Y; (2012) Synthesis and DNA binding properties of 1-(3-aminopropyl)-imidazole-containing triamide f-Im*PyIm: A novel diamino polyamide designed to target 5 '-ACGCGT-3 '. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 22 (18) pp. 5898-5902. 10.1016/j.bmcl.2012.07.071.

Sengerová, B; Allerston, CK; Abu, M; Lee, SY; Hartley, J; Kiakos, K; Schofield, CJ; (2012) Characterization of the human SNM1A and SNM1B/Apollo DNA repair exonucleases. Journal of Biological Chemistry , 287 (31) 26254 -26267. 10.1074/jbc.M112.367243. Green open access

Silini, A; Ghilardi, C; Figini, S; Sangalli, F; Fruscio, R; Dahse, R; Pedley, RB; (2012) Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. CELLULAR AND MOLECULAR LIFE SCIENCES , 69 (7) pp. 1167-1178. 10.1007/s00018-011-0862-8.

Spanswick, VJ; Lowe, HL; Newton, C; Bingham, JP; Bagnobianchi, A; Kiakos, K; Craddock, C; (2012) Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer , 12 , Article 436. 10.1186/1471-2407-12-436. Green open access

Staples, CJ; Myers, KN; Beveridge, RD; Patil, AA; Lee, AJ; Swanton, C; Howell, M; (2012) The centriolar satellite protein Cep131 is important for genome stability. J Cell Sci , 125 (Pt 20) pp. 4770-4779. 10.1242/jcs.104059.

Swanton, C; (2012) Intratumor Heterogeneity: Evolution through Space and Time. CANCER RESEARCH , 72 (19) pp. 4875-4882. 10.1158/0008-5472.CAN-12-2217.


Thirlwell, C; Feber, A; Lechner, M; Teschendorff, AE; Beck, S; (2012) Comments on: Interpretation of genome-wide infinium methylation data from ligated DNA in formalin-fixed paraffin-embedded paired tumor and normal tissue. BMC Res Notes , 5 631-. 10.1186/1756-0500-5-631. Gold open access

Tsochatzis, EA; Meyer, T; Burroughs, AK; (2012) Hepatocellular carcinoma. N.Engl.J.Med. , 366 (1) 92 - 93. 10.1056/NEJMc1112501#SA2.

Tzenaki, N; Andreou, M; Stratigi, K; Vergetaki, A; Makrigiannakis, A; Vanhaesebroeck, B; Papakonstanti, EA; (2012) High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation. FASEB J , 26 (6) pp. 2498-2508. 10.1096/fj.11-198192.


Vanhaesebroeck, B; Stephens, L; Hawkins, P; (2012) PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol , 13 (3) pp. 195-203. 10.1038/nrm3290.

Vermeer, LS; Fruhwirth, GO; Pandya, P; Ng, T; Mason, AJ; (2012) NMR metabolomics of MTLn3E breast cancer cells identifies a role for CXCR4 in lipid and choline regulation. J Proteome Res , 11 (5) pp. 2996-3003. 10.1021/pr300111x.


Walker-Samuel, S; Johnson, SP; Pedley, B; Lythgoe, MF; Golay, X; (2012) Extracranial measurements of amide proton transfer using exchange-modulated point-resolved spectroscopy (EXPRESS). NMR IN BIOMEDICINE , 25 (6) pp. 829-834. 10.1002/nbm.1798.

Walker-Samuel, S; Ramasawmy, R; Wells, J; Siow, B; Johnson, SP; Pedley, RB; Lythgoe, MF; (2012) Non-invasive Measurement of Tumour Interstitial Fluid Pressure Using Magnetic Resonance Imaging. In: (Proceedings) 22nd Biennial Congress of the European-Association-for-Cancer-Research. (pp. S96-S96). ELSEVIER SCI LTD

Wang, Y; Wang, XD; Lapi, E; Sullivan, A; Jia, W; He, YW; Ratnayaka, I; (2012) Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci U S A , 109 (33) pp. 13325-13330. 10.1073/pnas.1120193109.

Weatherstone, K; Meyer, T; (2012) Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Targeted Oncology , 7 (3) pp. 161-168. 10.1007/s11523-012-0224-y.

Whelan, JS; Jinks, RC; McTiernan, A; Sydes, MR; Hook, JM; Trani, L; Uscinska, B; (2012) Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. ANNALS OF ONCOLOGY , 23 (6) pp. 1607-1616. 10.1093/annonc/mdr491.

Whitehead, MA; Bombardieri, M; Pitzalis, C; Vanhaesebroeck, B; (2012) Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter. Biochem J , 443 (3) pp. 857-867. 10.1042/BJ20112214.

Windsor, RE; Strauss, SJ; Kallis, C; Wood, NE; Whelan, JS; (2012) Germline Genetic Polymorphisms May Influence Chemotherapy Response and Disease Outcome in Osteosarcoma. CANCER , 118 (7) pp. 1856-1867. 10.1002/cncr.26472.

Windsor, RE; Strauss, SJ; Kallis, C; Wood, NE; Whelan, JS; (2012) Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study. Cancer , 118 (7) pp. 1856-1867. 10.1002/cncr.26472.


Yang, J; Staples, O; Thomas, LW; Briston, T; Robson, M; Poon, E; Simoes, ML; (2012) Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. JOURNAL OF CLINICAL INVESTIGATION , 122 (2) pp. 600-611. 10.1172/JCI58780.

Yap, TA; Gerlinger, M; Futreal, PA; Pusztai, L; Swanton, C; (2012) Intratumor Heterogeneity: Seeing the Wood for the Trees. SCIENCE TRANSLATIONAL MEDICINE , 4 (127) 10.1126/scitranslmed.3003854.

Young, RJ; Tin, AW; Brown, NJ; Jitlal, M; Lee, SM; Woll, PJ; (2012) Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. BRITISH JOURNAL OF CANCER , 106 (6) pp. 1153-1159. 10.1038/bjc.2012.50.

This list was generated on Sun Dec 4 03:35:08 2016 GMT.